These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23573520)

  • 1. [Analysis of drug therapy of lung cancer in Hungary].
    Moldvay J; Rokszin G; Abonyi-Tóth Z; Katona L; Kovács G
    Magy Onkol; 2013 Mar; 57(1):33-8. PubMed ID: 23573520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer drug therapy in Hungary - 3-year experience.
    Moldvay J; Rokszin G; Abonyi-Tóth Z; Katona L; Fábián K; Kovács G
    Onco Targets Ther; 2015; 8():1031-8. PubMed ID: 25999737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
    Ramalingam S; Belani C
    Oncologist; 2008; 13 Suppl 1():5-13. PubMed ID: 18263769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on salvage therapy for non-small-cell lung cancer.
    Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
    Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
    Ho C; Ramsden K; Zhai Y; Murray N; Sun S; Melosky B; Laskin J
    J Thorac Oncol; 2014 Aug; 9(8):1180-6. PubMed ID: 25157771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Kotsakis A; Hatzidaki D; Vamvakas L; Vardakis N; Kalykaki A; Bozionelou V; Androulakis N; Kalbakis K; Saridaki Z; Georgoulias V; Agelaki S
    Anticancer Res; 2010 Oct; 30(10):4335-42. PubMed ID: 21036760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
    Sun JM; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Lee JS; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2010 Jun; 68(3):427-32. PubMed ID: 19674811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
    Walzer S; Chouaid C; Lister J; Gultyaev D; Vergnenegre A; de Marinis F; Meng J; de Castro Carpeno J; Crott R; Kleman M; Ngoh C
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):121-8. PubMed ID: 25248391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
    Bischoff HG; Heigener DF; Walzer S; Nuijten M
    Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
    Besse B; Soria JC; Le Chevalier T
    Ann Oncol; 2005 Jul; 16(7):997-8. PubMed ID: 15946975
    [No Abstract]   [Full Text] [Related]  

  • 15. A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
    Quan R; Huang J; Chen N; Fang W; Hu Z; Zhan J; Zhou T; Zhang L; Zhang H
    Tumour Biol; 2016 Aug; 37(8):11479-84. PubMed ID: 27012553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
    Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
    J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
    Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
    J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second-line treatment for advanced non-small-cell lung cancers].
    Akita H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):15-8. PubMed ID: 15675575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
    J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.